CHEK2 and glioma: Checkpoint kinase 2 (Chek2) mediates therapeutic resistance to CD8+ T cell recognition, and both genetic depletion or pharmacologic inhibition of Chek2 increase survival in combination with immune checkpoint blockade through STING activation in preclinical glioma models (21).